Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Tronnier

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistryClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der ImmunhistologieClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 25, 2024
S2k guideline basal cell carcinoma of the skin (update 2023)Berenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und NachsorgeBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 8, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und DiagnostikBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-upBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 29, 2018
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and DiagnosisBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
The Journal of Investigative Dermatology|November 12, 2018
Altered Notch Signaling in Dowling-Degos Disease: Additional Mutations in POGLUT1 and Further Insights into Disease PathogenesisDamian J Ralser, Hideyuki Takeuchi, Günter Fritz, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistryClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der ImmunhistologieClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 25, 2024
S2k guideline basal cell carcinoma of the skin (update 2023)Berenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und NachsorgeBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 8, 2019
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und DiagnostikBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 15, 2019
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-upBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 29, 2018
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and DiagnosisBerenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.
The Journal of Investigative Dermatology|November 12, 2018
Altered Notch Signaling in Dowling-Degos Disease: Additional Mutations in POGLUT1 and Further Insights into Disease PathogenesisDamian J Ralser, Hideyuki Takeuchi, Günter Fritz, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Pageof 8